Seagen announces positive chmp opinion for tukysa® (tucatinib) for the treatment of patients with locally advanced or metastatic her2-positive breast cancer

Bothell, wash.--(business wire)--seagen inc. (nasdaq:sgen) today announced that the committee for medicinal products for human use (chmp) of the european medicines agency adopted a positive opinion recommending the approval of tukysa® (tucatinib) in combination with trastuzumab and capecitabine for the treatment of adult patients with her2-positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-her2 treatment regimens. tukysa is an oral, small molecule tyro
SGEN Ratings Summary
SGEN Quant Ranking